HANALL BIOPHARMA CO.,LTD
Financials
Valuation Metrics
HANALL BIOPHARMA CO.,LTD's Market Cap is ₩2.5T. At end of 2025 it was ₩2.3T. Ranked #179 of 2,421 in KR market (top 7%), #146 of 781 on KOSPI (top 19%), #16 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.49T KRW | KR#179/2,421 Sec#16/231 |
| Revenue | 162.66B KRW | KR#1,133/2,421 Sec#67/231 |
| Net Income | -24.90B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 240.51B KRW | KR#1,168/2,421 Sec#82/231 |
| Net Assets | 161.63B KRW | KR#1,089/2,421 Sec#77/231 |
| Employees | 318 | KR#756/2,421 Sec#65/231 |
| Value | ||
| P/B | 15.43x | KR#2,395/2,421 Sec#219/231 |
| P/S | 15.34x | KR#2,319/2,421 Sec#178/231 |
| EV/EBITDA | 525.95x | KR#1,553/2,421 Sec#110/231 |
| FCF Yield | -0.13% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -15.41% | KR#2,027/2,421 Sec#154/231 |
| ROA | -10.35% | KR#2,113/2,421 Sec#162/231 |
| Op. Margin | 2.93% | KR#1,260/2,421 Sec#91/231 |
| Revenue Growth | 8.38% | KR#992/2,421 Sec#97/231 |
| Earnings Growth | -1215.12% | KR#1,332/2,421 Sec#95/231 |
| Financial Health | ||
| Debt Ratio | 48.81% | KR#944/2,421 Sec#107/231 |
| Total Debt | 44.09B KRW | KR#1,050/2,421 Sec#72/231 |
| FCF | -3.29B KRW | KR#1,408/2,421 Sec#111/231 |
| Cash | 30.20B KRW | KR#1,006/2,421 Sec#69/231 |
| Current Ratio | 1.49x | KR#1,209/2,421 Sec#130/231 |
| Net Debt/EBITDA | 2.91x | KR#906/2,421 Sec#66/231 |
| Performance | ||
| 1Y Return | 47.60% | KR#273/2,421 Sec#14/231 |
| 1M Return | -19.34% | KR#2,296/2,421 Sec#208/231 |
| From 52W High | -34.59% | KR#687/2,421 Sec#45/231 |
| 1Y MDD | -44.84% | KR#766/2,421 Sec#62/231 |
| Trading | ||
| Volume | 195,473 shares | KR#500/2,421 Sec#33/231 |
| Trading Value | 9.47B KRW | KR#262/2,421 Sec#21/231 |
| Foreign Own. | 3.92% | KR#1,067/2,421 Sec#96/231 |
| Per Share | ||
| EPS | -477 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,094 KRW | KR#1,841/2,421 Sec#138/231 |
Company Info
Hanall Biopharma is a pharmaceutical company established in 1973 and listed on the Korea Exchange in 1989. It manages overseas clinical trials and licensing for new drugs through its U.S. subsidiary, HPI. The company manufactures and sells over 160 pharmaceutical products for endocrine, circulatory, and other systems, while researching diverse new drugs, including antibody-based therapies for autoimmune diseases. By strengthening its R&D infrastructure with First-in-Class biosimilar drug research, dedicated personnel, and expanded facilities, Hanall Biopharma is enhancing its global market competitiveness. It is headquartered in Daedeok-gu, Daejeon.